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ABSTRACT  17 
Interest has been rekindled in the old antibiotic fosfomycin, partly because of its 18 
ability to penetrate biofilm. Using a transcriptomic approach, we investigated the 19 
modifications induced by fosfomycin in sessile cells of a clinical S. aureus isolated 20 
from a device associated infection. Cells still able to form biofilm after 4h of 21 
incubation in the presence of sub-inhibitory concentrations of fosfomycin and cells 22 
from 24h-old biofilm later submitted to fosfomycin had 6.77% and 9.41%, 23 
respectively, of differentially expressed genes compared to their antibiotic-free 24 
control. Fosfomycin induced mostly down-regulation of genes assigned to nucleotide, 25 
amino acid and carbohydrate transport and metabolism. Adhesins and capsular 26 
biosynthesis proteins encoding genes were down-regulated in fosfomycin-grown 27 
biofilm, whereas the murein hydrolase regulator lgrA and a D-lactate dehydrogenase-28 
encoding gene were up-regulated. In fosfomycin-treated biofilm, the expression of 29 
genes encoding adhesins, the cell wall biosynthesis protein ScdA and to a lesser 30 
extent the fosfomycin target MurA was also decreased. Unattached cells surrounding 31 
fosfomycin-grown biofilm showed greater ability to form aggregates than their 32 
counterparts obtained without fosfomycin. Reducing their global metabolism and 33 
lowering cell-wall turnover would allow some S. aureus cells to grow in biofilm 34 
despite fosfomycin stress while promoting hyperadherent phenotype in the vicinity of 35 
the fosfomycin-treated biofilm.  36 
 37 
 38 
 39 
 40 
 41 
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 42 
Introduction 43 
Chronic human infectious diseases are commonly caused by biofilm-forming bacteria 44 
such as Staphylococcus aureus (1) in prosthetic joint infections (PJIs), owing to the 45 
pathogen’s ability to colonize the implants.  46 
Bacteria inside biofilms have increased resistance not only to the action of the innate 47 
and adaptive immune defense systems, but also to the action of antimicrobial agents 48 
(2). Several factors are responsible for biofilm-associated resistance, including the 49 
density and the physiological state of the cells and the physical structure of the 50 
biofilm. The biofilm matrix can also act as a barrier to diffusion and thus reduces 51 
penetration of antibiotics into biofilms. The effectiveness of this barrier varies 52 
between antibiotics; gentamicin, tigecycline and daptomycin penetrate better than 53 
clindamycin, linezolid and vancomycin (3, 4). The effects of antibiotics can also be 54 
affected by the particular microenvironment of biofilm, such as acidic pH and low 55 
levels of oxygen encountered in the deep layers of the aggregates (5). Moreover, the 56 
presence of antibiotics can per se enhance biofilm formation, particularly at sub-57 
minimum inhibitory concentrations (sub-MIC) (6–9) and thus contributes to treatment 58 
failure.  59 
MICs are determined in vitro with planktonic cells growing exponentially under 60 
conditions that are optimal for the action of the drug but do not provide a true 61 
estimation of the concentration of antibiotics required to treat a bacterial biofilm. In 62 
vitro and in vivo experiments demonstrated that minimum bactericidal concentrations 63 
for biofilm bacterial cells are usually much higher (about 10-10,000 times) than their 64 
counterpart planktonic cells (4, 10) and therefore impossible to reach by conventional 65 
antibiotic administration. A combination of antibiotics with different and synergic 66 
4/31 
 
killing mechanisms is the best current solution for the treatment of biofilm infections. 67 
Rifampicin and mainly fosfomycin-based combinations have shown enhanced activity 68 
in vitro against biofilm-embedded Staphylococcus aureus isolates (11, 12). Several 69 
studies have evaluated the effect of rifampicin on the biofilm but little is known about 70 
the action of fosfomycin. 71 
Fosfomycin is an old antimicrobial agent with powerful bactericidal activity against 72 
several Gram-negative and Gram-positive bacteria (13, 14). It has recently rekindled 73 
interest as a treatment option for infections caused by multiple drug resistant (MDR) 74 
bacteria (15–17). Fosfomycin inhibits the initial step in peptidoglycan synthesis by 75 
inactivating the cytosolic uridine diphosphate (UDP)-N-acetylglucosamine 76 
enolpyruvyl transferase (MurA), thereby preventing the formation of UDP-N-77 
acetylglucosamine-3-O-enolpyruvate from UDP-N-acetylglucosamine and 78 
phosphoenolpyruvate (PEP), which ultimately leads to bacterial cell lysis (18). 79 
Fosfomycin is able to penetrate biofilm and several studies have reported a positive 80 
effect against biofilm (16) but the underlying mechanisms involved remain to be 81 
elucidated. Our previous work indicated that fosfomycin at sub-MICs inhibited in vitro 82 
biofilm formation by a S. aureus strain isolated from a bone infection while viable but 83 
unattached cells were still detectable in the suspensions covering the biofilm, even at 84 
the highest antibiotic concentrations tested (4).  85 
The aim of the present study was to investigate the mechanisms by which fosfomycin 86 
influences biofilm formation and affects a 24h-old biofilm of S. aureus. RNA 87 
sequencing (RNA-Seq) technology was used to compare the transcriptomes of S. 88 
aureus biofilms formed or treated with sublethal concentrations of fosfomycin. We 89 
also investigated the ability of non-adhering biofilm surrounding bacteria to form 90 
biofilm after fosfomycin treatment, since this portion of the population could be 91 
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involved in the development of chronic and recurrent infections. 92 
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MATERIALS AND METHODS 93 
 94 
Bacterial strain and growth conditions 95 
Methicillin-susceptible S. aureus (MSSA) strains isolated from patients suffering from 96 
PJI were used (LYO-S2, LYO-S22 and LYO-S31) (4). The whole-genome of strain 97 
LYO-S2 has been deposited at DDBJ/EMBL/GenBank under the accession number 98 
FCOV01000001 to FCOV01000024 (19). The isolates were stored at −80°C in 99 
Trypticase Soy (TS) broth containing 15% glycerol (v/v) and were subcultured onto 100 
Columbia agar (bioMérieux, Marcy l’Etoile, France). Further cultures were performed 101 
with TS agar (TSA) (Conda, Madrid, Spain) or modified Mueller-Hinton (mMH) 102 
(bioMérieux, Saint Louis, USA) broth. 103 
Fosfomycin disodium (Ercros, New York, USA) was used supplemented with 104 
glucose-6-phosphate (G6P) (Sigma-Aldrich, St Louis, USA). Vancomycin 105 
chlorhydrate was provided by Sigma-Aldrich (St Louis, USA). The Minimal Inhibitory 106 
Concentration (MIC) of fosfomycin for strain LYO-S2 was 4 mg/L and its Minimal 107 
Biofilm Eradication Concentration superior to 25,600 mg/L (4). 108 
 109 
Biofilm formation  110 
Biofilms were formed on polystyrene pegs of an MBECTM device (Innovotech, 111 
Edmonton, Canada) or on polystyrene disc coupons in a CDC Biofilm Reactor device 112 
(BioSurface Technologies Corp, Bozeman, USA).  113 
When the MBECTM device was used, biofilms were formed on polystyrene pegs of 114 
the cover with a bacterial inoculum of 8x105 CFU/mL in mMH broth supplemented 115 
with 25 µg/mL of G6P without or with 0.25µg/mL of fosfomycin. After 4h of incubation 116 
at 37°C with slow shaking (6 rpm per min), the capacity of non-adhering bacteria 117 
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surrounding the biofilm to form new aggregates was determined by harvesting and 118 
rinsing the cells with saline, transferring them to new microtiter plates at a bacterial 119 
inoculum of 106 CFU/mL in mMH broth. After 1 to 4h incubation at 37°C with shaking, 120 
aggregates formed on the pegs were rinsed with saline, transferred to new microtiter 121 
plates, and the number of sessile viable, culturable cells was counted by plating 122 
serial dilutions on TS agar after sonication.   123 
For the assays with the CDC Biofilm Reactor device, biofilms were formed for 4h on 124 
polystyrene disc coupons with a bacterial inoculum of 107 CFU/mL in mMH 125 
supplemented with 25 µg/mL of G6P and supplemented when necessary with 0.25 126 
µg/mL of fosfomycin or in mMH supplemented with 0.5 µg/mL of vancomycin.  127 
To assess the effect of fosfomycin on mature biofilm, 24h-old biofilms formed without 128 
antibiotics on polystyrene disc coupons of CDC Biofilm Reactor device were further 129 
incubated for 24h in the presence of 16 µg/mL of fosfomycin and 25 µg/mL of 130 
glucose-6-phosphate or in the presence of 8 µg/mL of vancomycin.  131 
 132 
RNA extraction  133 
After incubation at 37°C with shaking, biofilms formed on the polystyrene disc 134 
coupons of the CDC Biofilm Reactor device were rinsed with saline, transferred to 135 
saline and sonicated. To have enough biomass for RNA extraction, 24h-old biofilm 136 
treated with or without fosfomycin from both reactors were pooled for each sample. 137 
The resulting cell suspensions were filtered with the Swinnex Filter Holder system 138 
(0.2 µm – Millipore, Molsheim, France). The filters were then transferred into RNA 139 
extraction buffer: glucose 50 mM, Ethylenediaminetetraacetic acid (EDTA) 10 mM, 140 
Tris(hydroxymethyl)aminomethane (Tris) 25 mM pH = 8 into RNAse-free water 141 
(ThermoFisher Scientific, Waltham, Massachusetts, USA). After mechanical shaking 142 
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to disperse the cells, the filters were removed and EDTA 0.5M pH = 8 was added. 143 
After vigorous mixing, lysozyme (50 mg/mL – Euromedex, Souffelweyersheim, 144 
France) was added and incubated for 15 min at 37°C with gentle shaking. Sodium 145 
dodecyl sulfate (SDS) 20% (ThermoFisher Scientific) was then added and the 146 
mixture incubated for 5 min at room temperature without shaking. Cells were 147 
transferred into Precellys tubes containing beads with one volume of phenolic acid/ 148 
chloroform (ThermoFisher Scientific) for mechanical lysis with the PreCellys 24 149 
system (Bertin Technologies, Montigny le Bretonneux, France) at a speed of 6,000 150 
rocks per minute for two consecutive cycles of 30 s. After centrifugation for 5 min at 151 
20,000 g at 4°C, the aqueous phase was recovered and transfered to a tube 152 
containing 1 volume of chloroform (ThermoFisher Scientific).  After centrifugation for 153 
5 min at 20,000 g at 4°C, the aqueous phase was recovered and transfered to a tube 154 
containing a 1/10 volume of ammonium acetate 5M and 2 volumes of ethanol 100% 155 
(ThermoFisher Scientific). The samples were incubated overnight at -20°C. After 156 
centrifugation for 20 min at 20,000 g at 4°C, the supernatant was removed and the 157 
pellet washed with ethanol 70%. After centrifugation for 10 min at 20,000 g at 4°C, 158 
the RNA pellets were dried with a SpeedVac Vacuum Concentrator device (Genevac 159 
Ltd, Ipswich, United Kingdom). The RNA pellets were dissolved into RNAse-free 160 
water and treated with 10 units of TURBO DNAse (ThermoFisher Scientific). After a 161 
second phenol-chloroform extraction and ethanol precipitation, RNA pellets were 162 
suspended in RNAse-free water. RNA concentrations were quantified with the Qubit 163 
System ThermoFisher Scientific) and RNA quality was assessed with Agilent RNA 164 
6000 Pico Chip (Agilent Technologies, Santa Clara, USA). Ribosomal RNA was 165 
removed from each total RNA sample with the RiboZero kit (Bacteria – Illumina, San 166 
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Diego, California, USA) by GenoScreen (Lille, France). Three biological replicates 167 
were assessed for each condition.  168 
 169 
RNA sequencing and idenfication of differentially expressed genes  170 
RNA-sequencing (RNAseq) was performed by GenoScreen (Lille, France). Libraries 171 
were produced by the ScriptSeq Complete Kit (Bacteria - Illumina) and sequenced 172 
with the Hiseq2500 system (Illumina) with a paired-end protocol and read lengths of 173 
100bp. Reads were mapped against the genome of the reference strain S. aureus 174 
NCTC 8325 with Bowtie2 v2.2.6 software. Only reads without mismatch were 175 
counted. Differentially expressed genes between biofilm treated with fosfomycin and 176 
its untreated control were determined by RSEM v1.2.23 software. Genes with an 177 
adjusted p-value < 0.01 and |fold-change| > 2 were considered as being differentially 178 
expressed. RNA seq was performed with three independently isolated RNA samples. 179 
  180 
 181 
Transcriptome annotation   182 
Transcripts were identified with BLASTn searches against the reference strain S. 183 
aureus NCTC 8325 (NC_007795.1). The EggNog 4.5 database was used to obtain 184 
COG annotation for transcripts.  185 
 186 
RT-qPCR 187 
Reverse transcription was performed with 5 ng of total RNA prepared as described 188 
above. cDNA were obtained with iScript cDNA Synthesis kit (Bio-Rad, Hercules, 189 
California, USA) under the following conditions: 5 min at 25°C, 30 min at 42°C and 5 190 
min at 85°C. qPCRs were carried out in the CFX96 Real Time System (Bio-Rad, 191 
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Hercules, California, USA) with the SsoAdvanced SYBR Green Supermix (Bio-Rad) 192 
under the following conditions: initial denaturation at 95 °C for 30 s, and 40 cycles of 193 
5 s at 95 °C and 20 s at 59 °C in a total volume of 10 μL per well with 1X SYBR® 194 
Green, 625 nM of each gene-specific primer and 2 μL of 20X diluted cDNA. Primers 195 
were designed on the basis of S. aureus NCTC 8325 genome data and are listed in 196 
Table 1. Melting curve analysis was used to verify the specific single-product 197 
amplification. The gene expression levels were normalized relative to the expression 198 
levels of the gyrB housekeeping gene, and relative quantifications were determined 199 
with CFX Manager software v3.1 (Bio-Rad) by the E(−Delta Delta C(T)). The 200 
amplification efficiency (E) of each primer pair used for quantification was calculated 201 
from a standard amplification curve obtained with four dilution series of genomic 202 
DNA. All assays were performed in technical triplicates with three independently 203 
isolated RNA samples. 204 
 205 
Statistical analysis 206 
CFU measures were compared with Student's t-test. Correlation between RNAseq 207 
and RT-qPCR was analyzed by Pearson’s correlation test in GraphPad Prism 5. 208 
Fold-change (log10) values were used as a matrix to perform a heatmap with 209 
Heatmap.2 (gplots) with R sofware (version i386 3.2.4 Revised). Statistical analyses 210 
of RT-qPCR data were performed using the U Mann-Whitney test in GraphPad Prism 211 
5. 212 
 213 
Availability of supporting data  214 
The RNA-seq data sets supporting the results of this article have been deposited in 215 
NCBI’s Gene Expression Omnibus and are accessible through GEO Series 216 
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accession number GSE83269.  217 
 218 
 219 
RESULTS 220 
 221 
Transcriptome assembly and annotation 222 
Transcriptome studies were performed with two different S. aureus LYO-S2 223 
biofilm materials: biofilm cells formed for 4h in the presence of fosfomycin at sub-224 
MIC, and pre-formed 24h-old biofilm later submitted to sub-MBEC of fosfomycin for 225 
24 hours, hereafter referred to as fosfomycin-grown biofilm and fosfomycin-treated 226 
biofilm, respectively. Controls (without fosfomycin treatment) were run in parallel.  227 
About 11 and 13 million RNA-seq reads (minimum 100 bp each) were 228 
obtained for each sample: fosfomycin-treated biofilm and its control (not treated), 229 
fosfomycin-grown biofilm and its control (without fosfomycin), respectively. 230 
The genome sequence available for the S. aureus strain NCTC 8325 was used for 231 
mapping and to identify differentially expressed genes. Only reads aligned to the 232 
reference genome without any mismatch were counted. One triplicate of the 233 
fosfomycin-treated biofilm control generated less than 30% of reads that mapped 234 
with the genome reference and so was not taken into account for further analysis.  235 
More than 80% perfect matches were obtained for sequence reads of the fosfomycin-236 
grown biofilm sample, fosfomycin-treated biofilm sample and their respective 237 
controls.  238 
 239 
Transcriptome analysis  240 
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RNAseq analysis indicated that of the 2,538 annotated genes of S. aureus 241 
LYO-S2 deduced from the sequence of the reference strain NCTC 8325, 172 and 242 
239 were differentially expressed in fosfomycin-grown biofilm and in fosfomycin-243 
treated biofilm, respectively  (∣fold-change∣ > 2 and adjusted p-value < 0.01), with fold-244 
changes ranging from −35.7 to 25.9 (Table S1). Only 38 genes were shared by the 245 
two sets of comparison. To be highly specific, we focused mainly on genes 246 
differentially expressed with a│fold-change│> 5 (p-value < 0.01). 247 
Under these stringent conditions and after analysis of fosfomycin-grown 248 
biofilm, only 38 genes were differentially expressed (2 up- and 36 down-regulated) 249 
compared to the control (biofilm formed without fosmomycin). This clustering was 250 
further supported by the cluster structure as revealed by heatmap analysis (Figure 1). 251 
When categorized into different functional groups based on the COG database 252 
(Cluster of Orthologus Groups), 37 genes could be classified into 12 categories 253 
(Figure 2b). Among the latter, 43.6% were assigned to the COG category of 254 
metabolism, comprising essentially nucleotide and amino acid transport and 255 
metabolism, and 28.20% were assigned to the poorly characterized COG category. 256 
Twenty-three point one percent were assigned to the COG category of cellular 257 
processes and signaling, comprising essentially cell wall / membrane / envelope 258 
biogenesis. Only 5.1% were assigned to the COG category of information storage 259 
and processing, comprising essentially transcription and translation, ribosomal 260 
structure and biogenesis (Figure 2a).  261 
Analysis of fosfomycin-treated biofilm data showed that 52 genes were 262 
differentially expressed (13 up- and 39 down-regulated) compared to the control 263 
(without fosfomycin). This clustering was further supported by heatmap analysis 264 
(Figure 1). Categorization of the selected genes into different functional groups 265 
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based on the COG database indicated that only 49 of them could be classified into 266 
14 categories (Figure 2b). Among the latter, 65.3% were assigned to the COG 267 
category of metabolism comprising essentially nucleotide, amino acid and 268 
carbohydrate transport and metabolism. Fourteen point three percent were assigned 269 
to the COG poorly characterized category and 10.2% were assigned to the COG 270 
category of information storage and processing, comprising essentially translation, 271 
ribosomal structure and biogenesis. Finally, only 10.2% were assigned to the COG 272 
category of cellular processes and signaling (Figure 2b).  273 
Under the most stringent condition (│fold-change│> 5), only 12 genes were 274 
detected in both conditions (fosfomycin-grown biofilm and fosfomycin-treated biofilm 275 
versus their respective controls) and were down-regulated (Figure 1 and Table 2). 276 
Four of them belong to an operon that encodes proteins involved in purine 277 
biosynthesis, and another gene was identified as encoding a protein involved in 278 
pyrimidine biosynthesis. Two other genes belong to an operon that encodes proteins 279 
involved in arginine biosynthesis and two other genes in the same operon encoding 280 
ABC transporter were identified. Finally, three of them encode hypothetical or 281 
unknown proteins (Table 2). 282 
 283 
RNA-seq results verification by RT-qPCR 284 
To validate the RNAseq efficiency, eight genes differentially expressed with a 285 
│fold-change│> 5 were randomly selected and their relative expression levels 286 
determined by RT-qPCR with total RNA extracted from S. aureus LYO-S2 287 
fosfomycin-grown biofilm, fosfomycin-treated biofilm and their respective controls. 288 
Results indicated a likeness between fold-change obtained with RNAseq and RT-289 
qPCR (Figure 3). 290 
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RNAseq and RT-qPCR data for the eight genes tested in RT-qPCR were analyzed 291 
by a Pearson’s correlation test, which indicated a high correlation between RNAseq 292 
and RT-qPCR results with a r = 0.99 (p-value < 0.0001).   293 
 294 
 295 
Expression of target genes with biofilm extracts from two other S. aureus 296 
strains and in the presence of vancomycin  297 
RT-qPCRs were performed with a set of selected genes and extended to two other 298 
S. aureus strains (LYO-S31 and LYO-S22 in addition to LYO-S2); results are shown 299 
in Figure S1. The variation of expression of the target genes was quite similar 300 
between the three strains in the fosfomycin-grown biofilm condition (Figure S1b). 301 
More heterogeneous data were observed with fosfomycin-treated biofilm extracts 302 
(Figure S1a), although variations were comparable for some genes (scdA, fib-like), or 303 
involved only two strains out of the three tested in parallel (atl, lacC, PTS, purS, 304 
vraS).  305 
To determine how specific was the fosfomycin action on biofilm cells, we assessed 306 
the effect of another membrane targeting antibiotic, i.e. vancomycin, on LYO-S2 307 
biofilm cells. Globally vancomycin-grown biofilm and vancomycin-treated biofilm cells 308 
display different patterns of expression compared to their respective fosfomycin-309 
treated extracts (Figures S2a and b), with only a few statistically comparable levels of 310 
mRNA detected for PTS (PTS system lactose-specific transporter subunit), purS 311 
(phosphorybosylformylglycinamide synthase PurS), and fib-like (fibrinogen-binding 312 
protein like protein) in antibiotic-treated condition and atl (autolysin) in antibiotic-313 
grown biofilm condition. 314 
 315 
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Adhesion capacity of unattached cells surrounding fosfomycin-grown biofilm 316 
Determination of the adherence ability of these unattached cells indicated that 317 
they were more effective than their control (unattached cells harvested in the vicinity 318 
of biofilm formed in absence of fosfomycin) to form aggregates in a fairly short time 319 
(as of 1h) (Figure 4). 320 
 321 
DISCUSSION 322 
S. aureus LYO-S2 is a clinical strain isolated from a patient suffering from a 323 
PJI after total knee arthroplasty. The patient underwent three antibiotic treatments 324 
over 147 days including fosfomycin combined with oxacillin for 55 days in the middle 325 
of the treatment period. The outcome was favorable after 3-year clinical follow-up. 326 
We previously demonstrated this strain's ability to form biofilm in vitro, and the in vitro 327 
anti-biofilm activity of fosfomycin at sub-MICs (4). We also showed that the effective 328 
concentrations of fosfomycin required for 24h-old biofilm eradication were 329 
unattainable by conventional antibiotic administration (4). We therefore used S. 330 
aureus LYO-S2 as the model strain to study the molecular effects of fosfomycin on 331 
sessile cells using RNA-seq technology with both biofilm cells formed for 4h in the 332 
presence of fosfomycin at sub-MIC and pre-formed 24h-old biofilm cells later treated 333 
with sub-MBEC of fosfomycin for 24 hours. About 12 million RNA-seq reads were 334 
obtained for each sample, which is consistent with other studies that frequently 335 
obtained some 10 million reads per sample. In addition, with the exception of one set 336 
of data that was not included in the analysis, 80% of perfect matches were obtained 337 
when compared with the reference genome from S. aureus NCTC 8325, which 338 
illustrates the suitability of these RNA-seq results for comparative transcriptome 339 
analysis.  340 
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Previous transcriptional profiling studies performed with S. aureus strains and 341 
cell wall active antibiotics showed the induction of a "cell wall stress stimulon" 342 
(CWSS), i.e. a set of genes responding to cell wall active antibiotics but not to other 343 
external stresses such as temperature, osmotic and pH extremes (20). Fosfomycin 344 
acts on the first step of peptidoglycan biosynthesis pathway by irreversibly inhibiting 345 
MurA, an enolpyruvyl transferase. Petek et al. showed that this antibiotic at sub-MICs 346 
was able to up-regulate cell wall stress stimulon genes, including the genes encoding 347 
VraSR (Petek 2010). VraSR is a two-component sensory regulatory system that 348 
plays an essential role in the CWSS response, which leads to increased resistance 349 
against cell wall-active antibiotics (21). Dengler et al. showed that among several 350 
antibiotics tested fosfomycin triggered the highest induction of the promoters of  351 
CWSS genes in planktonic cells (22). In our study, the expression of vraSR was not 352 
modified whatever the tested condition (fosfomycin-grown biofilm and fosfomycin-353 
treated biofilm). This suggests that sessile cells are less affected by fosfomycin 354 
stress than their planktonic counterpart. Shen et al. already observed such 355 
discrepancies in response to another external stress (sub-inhibitory concentrations of 356 
Licochalcone A [LLA] a natural plant product) with an increased expression of vraSR 357 
in planktonic cells compared to their sessile counterparts (23). However, in our study, 358 
genes under the control of VraSR system were down-regulated, although to a small 359 
extent (with a │fold-change│> 2, Table S1), including murA in the fosfomycin-treated 360 
condition and mgt (encoding the monofunctional glycosyltransferase MGT) in the 361 
fosfomycin-grown condition. Since both enzymes are involved in peptidoglycan 362 
synthesis, this would reduce peptidoglycan synthesis within sessile cells. The 363 
quantity of peptidoglycan in S. aureus is also controlled by the activity of autolysins, 364 
mainly the murein hydrolase Atl, which is involved in cell wall turnover, cell division, 365 
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cell separation and biofilm formation. In our study, the expression of atl was down- 366 
regulated with a │fold-change│> 2 in presence of the antibiotic under the two tested 367 
conditions (fosfomycin-grown biofilm and fosfomycin-treated biofilm). The presence 368 
of fosfomycin, in addition to impairing the synthesis of peptidoglycan, could prevent 369 
its degradation in sessile cells. Similar observations were made with planktonic S. 370 
aureus cells treated with different cell-wall-active antibiotics (20, 21). In our study, the 371 
gene encoding a regulator of murein hydrolase LrgA was up-regulated under the 372 
fosfomycin-grown biofilm condition. This regulator negatively regulates murein 373 
hydrolase activity (24). Thus, by preventing further degradation of peptidoglycan 374 
under fosfomycin stress, some sessile cells would keep their peptidoglycan integrity 375 
despite the decreased expression of the peptidoglycan biosynthesis pathway enzyme 376 
gene, and would contribute to biofilm growth.  377 
Treatment with fosfomycin not only modified the expression of peptidoglycan 378 
synthesis-related genes but also that of genes involved in surface structure 379 
synthesis. Lower levels in the expression of the protein A encoding gene spa and in 380 
the expression of two genes encoding proteins involved in capsular polysaccharide 381 
biosynthesis (including Cap8C protein) were observed when biofilm was formed in 382 
the presence of fosfomycin and with fosfomycin-grown biofilm sessile cells, 383 
respectively. Similar results were obtained by Petek et al. with sub-MICs of 384 
fosfomycin and S. aureus planktonic cells (25). Qin et al. also showed that biofilm 385 
cells challenged with resveratrol respond with a significant under-expression of 386 
genes encoding capsular polysaccharide biosynthesis proteins (26). Although opinion 387 
differs on the role of the capsule (27), these two surface structures are important 388 
virulence factors that play multiple roles in bacterial adherence and biofilm formation 389 
by S. aureus. Hence, reduction in the expression of their encoding genes is likely to 390 
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result in a decrease in bacterial adhesion and biofilm formation, as observed in our 391 
study.  392 
Extension of our study to two other S. aureus strains showed that most target 393 
genes underwent similar changes in their expression (Figure S1), meaning that the 394 
data from the transcriptome analysis were not strain specific but correspond to a 395 
more general behavior. Additional assays performed with vancomycin instead of 396 
fosfomycin also revealed that the antibiotic stress responses induced by the two 397 
peptidoglycan-targeting molecules were different (Figure S2), probably related to the 398 
unique molecular response induced by each stress as previously demonstrated in a 399 
metabolomic approach (28). 400 
Numerous studies including ours have determined the impact of antibiotics on 401 
biofilm formation and sessile cell viability (6, 8). However, the concomitant outcome 402 
of non-adhering bacteria has been poorly investigated, despite the possibility that this 403 
portion of the population could actively participate in the development of chronic 404 
infections. For this reason, we also investigated in the present study the fate of 405 
unattached cells surrounding 4h-old biofilm, not knowing whether these cells were 406 
initially adhering to the biofilm or whether they remained unattached throughout the 407 
incubation time. Surprisingly, such cells harvested in the assay performed in the 408 
presence of fosfomycin had a greater ability to form aggregates than their 409 
counterparts obtained without fosfomycin. It is therefore tempting to speculate that 410 
sub-MICs of fosfomycin, while partially impairing bacterial incorporation within 411 
biofilms, also affect the non-adhering surrounding bacteria, giving rise to hyper 412 
adherent cells in the vicinity of the biofilm.   413 
A recent study characterizing the in vivo transcriptome of S. aureus cells 414 
isolated from the joint fluid of a PJI reported typical transcriptomic and metabolomic 415 
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patterns when compared to those of in vitro planktonic cells, with increased 416 
expression of virulence associated-genes (29). Bacteria harvested in the patient's 417 
joint fluid could correspond to unattached cells surrounding the biofilm formed on the 418 
prosthesis. However, any further comparison would be inappropriate since our study 419 
was conducted in aerobic conditions and PJI-associated biofilm formation and 420 
dissemination occur in anaerobic/hypoxic conditions, as illustrated by the elevated 421 
number of related catabolic pathways genes up-regulated in the study performed by 422 
Xu et al. (29). Nonetheless, therapeutic molecules used to prevent or cure S. aureus 423 
infections of prosthetic material should be effective against both sessile and free 424 
living cells to avoid emergence of biofilm-associated PJIs. In our study, the relative 425 
effectiveness of fosfomycin in the prevention of biofilm formation and against 24h-old 426 
biofilm was counterbalanced by a stimulating effect on the ability of unattached cells 427 
surrounding 4h-old biofilm to form new aggregates. Further investigation with a large 428 
panel of MRSA isolates is required to confirm these findings and determine whether 429 
fosfomycin has overall beneficial effects on the reduction of S. aureus biofilm-430 
mediated infections.   431 
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Legends of figures  537 
Figure 1. Heatmap with 80 differentially expressed genes with a │fold change│> 538 
5 in two different growth conditions of S. aureus biofilm (p-value adjusted < 539 
0.01). The fold-change was presented as a log10 fold-change between -1.5 and 1.5. 540 
Blue and red match to genes under- or overexpressed, respectively, in presence and 541 
absence of fosfomycin.  542 
 543 
Figure 2. Histogram of Clusters of Orthologous Group (COG) classification of 544 
the differentially expressed genes with a │fold change│> 5 (p-value adjusted < 545 
0.01) in two different growth conditions of S. aureus biofilm. (a) COG affiliation 546 
of genes differentially expressed between biofilm formed with or without fosfomycin. 547 
(b) COG affiliation of genes differentially expressed between 24h-old biofilm treated 548 
or not with fosfomycin. COG function classes are indicated along the x-axis and the 549 
number of genes differentially expressed for each COG function class along the y-550 
axis. COG function class: [C] Energy production and conversion, [D] Cell cycle 551 
control, cell division and chromosome partitioning,  [E] Amino acid transport and 552 
metabolism,  [F] Nucleotide transport and metabolism,  [G] Carbohydrate transport 553 
and metabolism,  [H] Coenzyme transport and metabolism, [J] Translation, ribosomal 554 
structure and biogenesis,  [K] Transcription,  [M] Cell wall/membrane/envelope 555 
biogenesis, [ND] COG classification not determined,  [O] Posttranslational 556 
modification, protein turnover and chaperones,  [P] Inorganic ion transport and 557 
metabolism,  [S] Function unknown, [T] Signal transduction mechanisms,  [U] 558 
Intracellular trafficking, secretion, and vesicular transport and  [V] Defense 559 
mechanisms.   560 
 561 
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Figure 3. Expression ratio (log10) obtained by RT-qPCR and RNAseq. Expression 562 
ratio obtained by RT-qPCR (black) and RNAseq (grey) of 8 genes differentially 563 
expressed between biofilm formed with or without fosfomycin and between 24h-old 564 
biofilm treated or not with fosfomycin. These genes encode [1] D-lactate 565 
dehydrogenase, [2] murein hydrolase regulator LgrA, [3] immunoglobulin G-binding 566 
protein Sbi, [4] amino acid ABC transporter ATP-binding protein, [5] dihydroorotate 567 
dehydrogenase 2, [6]  L-lactate dehydrogenase, [7]  ferritin and [8]  glycolytic operon 568 
regulator. gyrB was used as a reference gene for normalization of RT-qPCR data. All 569 
gene expression ratios from RT-qPCR between treatment groups and controls were 570 
significantly different (p-value < 0.05). The x-axis indicates the genes, and the y-axis 571 
shows the gene expression ratios. Bars represent the error standard (n=3). 572 
 573 
Figure 4. Determination of the ability of non-adhering S. aureus collected in the 574 
vicinity of biofilm to form aggregates by enumeration of viable bacteria. Non-575 
adhering cells surrounding biofilm formed without fosfomycin (control) are 576 
represented in black and non-adhering cells surrounding fosfomycin-grown biofilm 577 
are indicated in gray. Length of incubation (h) is indicated along the x-axis and cell 578 
viability along the y-axis (CFU/mL). Bars represent the error standard (n=3, each 579 
assay including at least three replicates) and the threshold of detection was 10 580 
CFU/ml. The significant differences between CFU/mL values were calculated by a 581 
Student test. *Significant differences (* p< 0.05 and *** p<0.001).  582 
 583 
 584 
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